PT - JOURNAL ARTICLE AU - Chitwood, Melanie H. AU - Colijn, Caroline AU - Yang, Chongguang AU - Crudu, Valeriu AU - Ciobanu, Nelly AU - Codreanu, Alexandru AU - Kim, Jaehee AU - Rancu, Isabel AU - Rhee, Kyu AU - Cohen, Ted AU - Sobkowiak, Benjamin TI - The recent rapid expansion of multidrug resistant strains of <em>Mycobacterium tuberculosis</em> Ural lineage 4.2 in the Republic of Moldova AID - 10.1101/2023.11.10.23298377 DP - 2023 Jan 01 TA - medRxiv PG - 2023.11.10.23298377 4099 - http://medrxiv.org/content/early/2023/11/10/2023.11.10.23298377.short 4100 - http://medrxiv.org/content/early/2023/11/10/2023.11.10.23298377.full AB - The projected trajectory of multidrug resistant tuberculosis (MDR-TB) epidemics depends on the reproductive fitness of circulating strains of MDR M. tuberculosis (Mtb). Previous efforts to characterize the fitness of MDR Mtb have found that Mtb strains of the Beijing sublineage (Lineage 2.2.1) may be more prone to develop resistance and retain fitness in the presence of resistance-conferring mutations than other lineages. Using Mtb genome sequences from all culture-positive cases collected over two years in Moldova, we estimate the fitness of Ural (Lineage 4.2) and Beijing strains, the two lineages in which MDR is concentrated in the country. We estimate that the fitness of MDR Ural strains substantially exceeds that of other susceptible and MDR strains, and we identify several mutations specific to these MDR Ural strains. Our findings suggest that MDR Ural Mtb has been transmitting efficiently in Moldova and poses a substantial risk of spreading further in the region.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis publication was made possible by CTSA Grant Number UL1 TR001863 from the National Center for Advancing Translational Science (NCATS), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained for this study from the Ethics Committee of Research of the Phthisiopneumology Institute in Moldova and the Yale University Human Investigation Committee (Number 2000023071).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors